Strangfeld, A <br/><br/>
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.  [electronic resource] 

 -  Annals of the rheumatic diseases  Mar 2017 
 - 504-510 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Observational Study 
<br/><br/><label>ISSN: </label>1468-2060 
<br/><br/><label>Standard No.: </label>10.1136/annrheumdis-2016-209773  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abatacept--therapeutic use<br/>Abdomen, Acute--epidemiology<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antirheumatic Agents--therapeutic use<br/>Arthritis, Rheumatoid--blood<br/>Biological Products--therapeutic use<br/>C-Reactive Protein--metabolism<br/>Germany--epidemiology<br/>Humans<br/>Incidence<br/>Intestinal Perforation--blood<br/>Middle Aged<br/>Prospective Studies<br/>Registries<br/>Risk Assessment<br/>Rituximab--therapeutic use<br/>Sigmoid Diseases--blood<br/>Single-Blind Method<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors